Neuropsychiatric Disease and Treatment

Dovepress
Taylor & Francis Group

Open Access Full Text Article

REVIEW

Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes

Karina Erlianti[1–3], Mohammed Alfaqeeh[1,2], Irma Melyani Puspitasari[2,4], Fredrick Dermawan Purba[5], Auliya A Suwantika[2,4,6]

[1]Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia; [2]Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia; [3]Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Islam Kalimantan Muhammad Arsyad Al Banjari, Banjarmasin, South Kalimantan, Indonesia; [4]Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia; [5]Department of Psychology, Faculty of Psychology, Universitas Padjadjaran, Bandung, Indonesia; [6]Center for Health Technology Assessment, Universitas Padjadjaran, Bandung, Indonesia

Correspondence: Auliya A Suwantika, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jalan Raya Bandung-Sumedang KM 21, Bandung, 45363, Indonesia, Tel/Fax +62-878-2267-1010, Email auliya@unpad.ac.id

Abstract: Treatment-resistant schizophrenia (TRS) affects up to 30% of individuals with schizophrenia who fail to respond to standard antipsychotics. This narrative review summarizes current evidence on clozapine's clinical effectiveness, economic impact, and quality-of-life benefits. A nonsystematic literature review of PubMed, Scopus, and Google Scholar was performed using relevant clinical and health-economic keywords. Findings consistently demonstrate that clozapine provides superior symptom reduction, reduces rehospitalization and mortality, and improves functional recovery and patient-reported outcomes. Evidence from real-world studies and meta-analyses shows marked reductions in rehospitalization rates, mortality, and caregiver burden compared with other antipsychotics. Economic analyses confirm that, although clozapine requires ongoing hematologic monitoring, its long-term savings from reduced inpatient care, emergency visits, and indirect productivity losses outweigh these costs, establishing its cost-effectiveness across diverse health-system settings. Despite its proven benefits, clozapine remains underused due to safety concerns, mandatory monitoring, limited prescriber confidence, and infrastructural barriers. Optimizing its use requires early identification of TRS, timely initiation of therapy, individualized monitoring strategies, and close interprofessional collaboration among psychiatrists, pharmacists, and healthcare teams. At the policy level, investment in laboratory infrastructure, subsidized monitoring programs, and the development of locally adapted treatment guidelines are critical to expanding safe, equitable, and sustainable access to clozapine worldwide.
Keywords: clozapine, antipsychotics, quality of life, adherence, pharmacoeconomics, mental health policy

Introduction

Treatment-Resistant Schizophrenia (TRS) is a complex and challenging clinical condition characterized by an inadequate response to at least two different antipsychotic treatments given at appropriate doses and durations.[1,2] Approximately 20–30% of individuals with schizophrenia meet TRS criteria, underscoring its clinical and public health significance.[3] Beyond its direct impact on individual mental health, TRS imposes a considerable burden on patients, families, and healthcare systems, including diminished quality of life, increased healthcare expenditures, and significant challenges in social functioning.[4] Individuals with TRS frequently experience persistent and severe symptoms that markedly impair their quality of life and social functioning.[5] Families often endure significant emotional and financial strain due to the demands of long-term care, while healthcare systems face increased costs and resource demands in managing these complex cases.[6,7]

Received: 9 September 2025
Accepted: 28 October 2025
Published: 8 November 2025

Clozapine is widely regarded as the first-line or "gold-standard" treatment for TRS, owing to its superior efficacy in symptom management.[8] It has demonstrated significant reductions in positive symptoms, such as hallucinations and delusions, even among patients who fail to respond to other antipsychotics. Studies have reported that approximately 70.5% of patients achieve at least a 20% reduction in symptoms.[9,10] It is uniquely approved for reducing suicidality and has been associated with improved long-term functioning and lower all-cause mortality.[11–13]

Long-term studies indicate that clozapine significantly improves overall functioning and quality of life. Patients treated with clozapine report better social integration, higher Quality of Life Scale scores, and lower all-cause mortality.[14] Despite these advantages, clozapine use remains limited due to safety concerns, monitoring requirements, and limited infrastructure. These include severe adverse effects such as agranulocytosis, myocarditis, and seizures, which necessitate regular hematological monitoring. Additional barriers include stigma, lack of clinician training, and insufficient monitoring infrastructure in many regions.[15]

Despite these challenges, clozapine remains the most effective treatment option for TRS.[16] From a quality-of-life perspective, reductions in severe symptoms and improvements in social functioning enhance patient well-being and alleviate family burden.[17] Economically, clozapine use may reduce long-term care costs by lowering relapse rates, hospital admissions, and emergency service utilization. Although its administration requires stringent monitoring protocols, such as routine blood tests to detect agranulocytosis,[18] many patients report positive experiences and prefer clozapine over other treatments due to its superior symptom control.[8]

While the clinical efficacy of clozapine is well-documented, its broader benefits, particularly its economic impact and influence on quality of life, have received less attention in the literature.[19] Most studies focus on symptom reduction, with limited integration of functional and cost-related outcomes.[20–22] Given the substantial burden of TRS on individuals and health systems, a comprehensive synthesis of clozapine's multidimensional impact is warranted. Therefore, this narrative review aims to comprehensively synthesize and discuss current evidence on clozapine's clinical efficacy, economic implications, and quality-of-life outcomes in treatment-resistant schizophrenia, in order to inform clinical practice and mental health policy development.

Methods

A nonsystematic literature review of English-language publications was conducted in PubMed, Scopus, and Google Scholar using the keywords: treatment-resistant schizophrenia, clozapine, antipsychotics, cost-effectiveness, quality of life, adverse effects, monitoring, implementation barriers, and health policy. Additional sources were identified from the reference lists of retrieved articles and relevant clinical guidelines. Evidence was summarized narratively to integrate clinical, economic, and quality-of-life perspectives, and recommendations were formulated based on consistency and relevance across the included sources.

Clozapine Clinical Outcome

Clozapine demonstrated consistent clinical benefits across most studies. For example, Verma et al (2020) reported significant reductions in Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) scores over a six-month follow-up period. Butler et al (2022) documented a 74.71% reduction in patient days alongside substantial decreases in PANSS score. Lee et al (2023) found that 70.5% of patients achieved at least a 20% reduction in BPRS score, with cognitive functioning remaining stable In the United States, Velligan et al (2015) observed that clozapine monotherapy reduced emergency department visits and outperformed polypharmacy regimens. Kim et al (2014) also noted significant improvements in depressive symptoms and subjective well-being. Across studies, average reductions of approximately 20–25% in PANSS scores indicate clinically meaningful improvements in symptom control.[23] In addition, the use of clozapine is associated with significant reductions in the CDSS, reflecting improvement in depressive symptoms.

Several studies provide quantitative evidence of clozapine's impact. For example, Verma et al (2021) noted a significant reduction in CGI-S scores from 5.46 to 3.46, shifting most patients from "markedly ill" to "mildly/moderately ill." CGI-I scores improved in 100% of patients, with 69.2% rated as "much" or "very much improved."

The CGI-Efficacy Index decreased from 12.63 to 6.05, indicating a favourable risk–benefit profile. Similarly, GAF scores improved from 35.56 to 56.42, highlighting gains in functional status and social functioning.

A study conducted by Kitagawa et al (2024) in Japan reported changes in prescribing patterns following the introduction of clozapine, including an increase in monotherapy and a decrease in polypharmacy, as well as a reduction in the use of antiparkinsonian agents and benzodiazepines.[24] Benzodiazepines are typically prescribed to patients with schizophrenia to manage antipsychotic-induced side effects such as acute agitation and extrapyramidal symptoms (including agitation, akathisia, and acute dystonia).[25,26] These findings suggest that clozapine use not only improves patients' clinical symptoms but also contributes to the rationalization of pharmacotherapy by reducing the burden of adjunctive medications required to manage antipsychotic side effects, such as antiparkinsonian agents and benzodiazepines. Regarding rehospitalization parameters, clozapine has been shown to reduce post-treatment hospitalization rates by nearly tenfold. A study showed that after 12 weeks of clozapine treatment, glutamate levels in the caudate nucleus of patients with TRS decrease significantly and correlate with symptom improvement.[27] Factors influencing clinical response to clozapine include plasma drug concentrations and immune dysfunction, both of which have been linked to treatment outcomes.[28–30] Clozapine has also demonstrated a 70.5% response rate in reducing psychotic symptoms, as measured by the Brief Psychiatric Rating Scale (BPRS). These findings confirm that clozapine remains the gold standard for treating TRS.[14] Moreover, it is recognized as the most effective monotherapy for TRS, given its ability to reduce suicide risk, improve patient satisfaction, and deliver superior clinical outcomes.[31]

Research on clozapine's role in dopamine-related conditions highlights its efficacy in treating dopamine supersensitivity psychosis, which is considered a hypothesized mechanism contributing to treatment resistance in schizophrenia rather than a distinct disorder. A study reported that 13 out of 15 patients with this condition experienced no relapse over 2.5 years of clozapine therapy.[32] Other work has confirmed clozapine's ability to lower hospitalization rates and reduce treatment changes among TRS patients, despite its association with risks such as diabetes and hyperlipidemia.[33] Clozapine's mechanism of action differs from other antipsychotics due to its unique interactions with muscarinic acetylcholine receptors, particularly M4 and possibly M1, rather than dopamine D2 or serotonin 5HT2A receptors. Unlike most antipsychotics, which primarily block D2 receptors, clozapine acts as a partial agonist at M4 receptors. Activation of M4 in the striatum inhibits neurotransmitter release, which may contribute to its superior antipsychotic effects.[34] Table 1 summarizes key studies evaluating clozapine's clinical effectiveness across multiple outcome parameters, providing further support for its role as the gold standard treatment in TRS.

Safety and Side Effects

The therapeutic benefits of clozapine are tempered by a range of potential adverse effects, making its safety profile a critical consideration in clinical practice. Despite its effectiveness, clozapine carries a risk of agranulocytosis, necessitating regular blood monitoring.[47] Beyond agranulocytosis, clozapine is also associated with other serious adverse effects such as myocarditis, seizures, sedation, and metabolic changes.[48–50] This side effect demands systematic evaluation and proactive management to avoid undermining treatment adherence.[51] Other work has confirmed clozapine's ability to lower hospitalization rates and reduce treatment changes among TRS patients, despite its association with risks such as diabetes and hyperlipidemia.[33]

From a cardiovascular perspective, a US study demonstrated significant increases in diastolic blood pressure and heart rate during clozapine treatment. Hypertension prevalence rose from 22% to 67%, and tachycardia from 33% to 83%, underscoring the need for routine monitoring to prevent complications.[52] In Yogyakarta, Indonesia, Raharjeng et al (2023) reported significant side effects of clozapine, including dizziness, vomiting, diarrhea, hypersalivation, weight gain, and sedation. Most side effects were manageable without discontinuation 72.2% of patients required adjunctive treatment, 24.1% required no additional therapy, and only 3.7% needed to stop treatment.[53]

Barriers also arise at both the clinician and health system levels. A survey of 100 psychiatrists in Karachi, Pakistan, found that 70% felt uncomfortable prescribing clozapine due to concerns about serious side effects, complex laboratory monitoring, and lack of specific training.[54] In many low- and middle-income countries, usage remains limited. The REAP Survey reported an average clozapine use rate of only 18.4%, with significant variation between countries (2.6% in Japan vs 32.3% in Hong Kong).[55]

https://doi.org/10.2147/NDT.S566527

Table 1 Summary of Clinical Outcomes of Clozapine in Treatment-Resistant Schizophrenia

Study	Country	Measures Used	Main Findings
Verma et al (2021)[22]	India	PANSS, CDSS, CGI, YBOCS	↓PANSS & CDSS scores; improved OCD symptoms (YBOCS), depressive symptoms (CGI).
Butler et al (2022)[35]	UK	PANSS, Outpatient Visits, HoNOS	↓PANSS (80 → 50.5); 74.7% ↓inpatient days; ↓outpatient visits.
Verma et al (2021)[36]	India	Patient and caregiver questionnaires	Improvedpsychopathology; improved sleep and interpersonal functioning.
Lee et al (2023)[10]	USA	BPRS, QLS, cognitive tests	70.5% ≥ 20% symptom reduction (BPRS); stable cognition except memory.
Kim et al (2014)[37]	South Korea	PANSS, BDI, SWN	↓Positive & negative PANSS; improved depressive symptoms (P<0.05).
Verma et al (2021)[38]	India	CGI, GAF	↓CGI-S (5.46 → 3.46); ↑GAF (35.6 → 56.4); 100% clinical improvement.
Kitagawa et al (2024)[24]	Japan	Prescribing patterns	↑Monotherapy; ↓polypharmacy, and adjunct benzodiazepine use
Pridan et al (2015)[39]	Israel	Rehospitalization Frequency	↓ Rehospitalization after clozapine initiation
Tiihonen et al (2019)[40]	Finland	Rehospitalization rates	↓Psychiatric rehospitalization vs other antipsychotics.
Wimberley et al (2017)[41]	Denmark	National registries, Cox models	↓All-cause mortality and ↓self-harm risk with clozapine vs non-clozapine.
Tiihonen et al (2017)[42]	Finland	Health registers; mortality, hospitalization	↓Mortality & ↓hospitalization in TRS patients treated with clozapine.
Vieira et al (2024)[43]	Brazil	Administrative data; Cox & Kaplan-Meier	↑Survival with clozapine vs non-clozapine; supports policy adoption in LMICs.
Cho et al (2019)[44]	UK	EHR, SLAM, ZTAS	↓All-cause mortality (HR = 0.61); better functioning and more monitoring.
Hatano et al (2023)[45]	Japan	Hospitalization rates, symptom scales	↓Hospitalizations & durable symptom improvement over 10 years post-initiation.
Peitl et al (2023)[46]	Croatia	CGI, PANSS	↓PANSS (100 → 67); ↓CGI (5.4 → 3.2) after 8 weeks + ECT in ultra-TRS.

Abbreviations: PANSS, Positive and Negative Syndrome Scale; CGI, Clinical Global Impression; CGI-S, CGI–Severity; CGI-I, CGI–Improvement; CGI-EI, CGI–Efficacy Index; CDSS, Calgary Depression Scale for Schizophrenia; YBOCS, Yale–Brown Obsessive Compulsive Scale; HONoS, Health of the Nation Outcome Scales; BPRS, Brief Psychiatric Rating Scale; QLS, Quality of Life Scale; BDI, Beck Depression Inventory; SWN, Subjective Well-Being under Neuroleptic Treatment Scale; GAF, Global Assessment of Functioning; SLAM, South London and Maudsley NHS Foundation Trust; ZTAS, Zaponex Treatment Access System; EHR, Electronic Health Records; TRS, Treatment-Resistant Schizophrenia; ECT, Electroconvulsive Therapy; HR, Hazard Ratio; LMICs, Low- and Middle-Income Countries; SIA, SIH, SIM, Brazilian Health System Administrative Databases; CI, Confidence Interval.

Specific populations require special consideration. In older adults (>65 years), clozapine use requires slower titration and lower doses (25–100 mg/day) to minimize the risks of orthostatic hypotension, sedation (which increases the risk of falls), anticholinergic effects such as constipation and delirium, and aspiration pneumonia due to hypersalivation.[56] Gender disparities also exist. A UK study found women were significantly less likely to be prescribed clozapine than men (adjusted OR = 0.66), even after adjusting for clinical and demographic factors.[57] Gender differences also influence side-effect profiles. An Italian study found women more frequently experienced constipation, orthostatic hypotension, and abdominal obesity, while men were more prone to tachycardia and hypertriglyceridemia.[58]

Behavioral factors and drug interactions further complicate clozapine use. A study in Japan found that smoking increased relapse risk among clozapine-treated patients (aHR = 2.27), which was dramatically higher when combined with valproic acid (aHR = 5.32). This underscores the need for a comprehensive assessment of patients' daily behaviors, such as smoking and cautious selection of combination therapies, especially with valproate in patients on clozapine.[59] Moreover, the TRRIP Consensus emphasizes ensuring plasma clozapine levels of ≥350 ng/mL before initiating augmentation. Agents such as amisulpride or aripiprazole are recommended for positive symptoms, SSRIs for negative symptoms, alongside psychosocial interventions such as CBT.[8] Research in Hong Kong supports using ≤300 mg/day dosing and multiple daily dosing to minimize cognitive side effects and enhance social functioning, reinforcing the need for personalized treatment strategies.[60] Overall, clozapine remains the first-line choice due to its unmatched efficacy in treating TRS. However, its use requires addressing multidimensional barriers, including prescriber training, subsidized laboratory monitoring costs, the development of dedicated clinics, local guideline adaptation, and age-, gender-, and comorbidity-sensitive side effect management. A systematic and integrated approach is needed to ensure wider, safer, and more equitable access to clozapine therapy.

Psychiatric pharmacists have a strategic role in overcoming barriers to clozapine use by enhancing prescriber knowledge, managing and minimizing side effects through vigilant monitoring, ensuring patient adherence through education and ongoing support, and advocating for inclusion of clozapine in formularies to broaden access. Additionally, implementing interprofessional care models can improve coordination among healthcare providers, significantly enhancing patient outcomes. At the system level, support is needed through increased resources and provider training, development of structured and efficient care pathways, and awareness campaigns promoting clozapine as an effective treatment option, including for younger patients with severe mental illness. Identifying existing barriers—clinical, administrative, and systemic—and implementing supportive structural changes are critical steps toward optimizing clozapine utilization in clinical practice.[14,61,62] Table 2 summarizes the safety findings and adverse effects, highlighting both common and serious complications such as sialorrhea, neutropenia, myocarditis, and metabolic changes, along with key notes on risk factors and clinical implications.

Quality of Life Outcome of Clozapine

Several studies have evaluated the impact of clozapine on quality of life (QoL) in patients with TRS, employing various assessment tools and methodological approaches. Overall, the evidence highlights clozapine's positive effects across multiple domains, including physical health, psychological well-being, social relationships, functional capacity, and environmental support. For instance, Verma et al (2021b) reported significant improvements in all domains of the WHOQOL-BREF following treatment with clozapine.[22] Similarly, Butler et al (2022), using real-world clinical data, demonstrated sustained benefits in mental, physical, and social functioning, accompanied by a reduction in healthcare utilization.[35] From the caregivers' perspective, Verma et al (2021) also found decreased levels of stress and caregiving burden, while patients themselves reported meaningful improvements in perceived quality of life.[36] Longitudinal study by Lee et al (2023) revealed a 72% increase in Qol scores, with 24% of patients achieving "good" levels of functioning and a significant reduction in suicidal ideation.[10] Qol improvements associated with clozapine may arise both directly, through alleviation of persistent symptoms, and indirectly, via reduced hospitalization rates and enhanced social or occupational functioning. However, not all findings were uniformly favorable. Li et al (2015) found no significant difference in QoL between TRS patients receiving clozapine and those treated with other antipsychotics, suggesting that individual response variability remains an important consideration.[74] These findings are further summarized in Table 3, which presents key QoL outcomes across studies evaluating clozapine in treatment-resistant schizophrenia.

https://doi.org/10.2147/NDT.S566527

Table 2 Summary of Safety Findings and Adverse Effects Reported in Clozapine Studies

Study (Author, Year)	Study Design	Sample Size	Safety Findings / Adverse Effects	Key Notes
Kelly et al (2024)[63]	Prospective, open-label clinical trial; weekly monitoring (ANC, WBC)	n=274	Sialorrhea (68%), neutropenia (0.36%)	Neutropenia significantly higher in ACKR1-null genotype ($p<0.001$)
Chandru et al (2023)[64]	Retrospective toxicology review; ADR documentation, ECG, blood counts	n=61	CNS symptoms, myocarditis, NMS, rhabdomyolysis	Clozapine-naïve patients more susceptible; onset < 8 hours
Iqbal et al (2020)[65]	Text-mining from EHR data	>2835 patients	Sedation, hypersalivation, tachycardia, constipation, and weight gain.	Smoking status influenced 21 of 33 ADRs
Harjaningsih et al (2023)[66]	Cross-sectional study	n=71	No significant correlation with dose/regimen/duration.	Female gender is significantly associated with obesity ($p<0.05$)
Imazu et al (2021)[67]	National registry analysis	>8000 patients	Neutropenia/leukopenia (5.0%), glucose intolerance, GI disturbances, sedation, seizures.	Most side effects occurred early in treatment
De Filippis et al (2021)[68]	5-year prospective study	n=21	No significant clinical decline. ↓ BMI (−8.98 kg).	Mild side effects were manageable
Zhuo et al (2021)[69]	16-week prospective cohort study; fasting glucose, PANSS	n=230	76.5% developed prediabetes/diabetes; metformin was effective in only 24.4%.	Poorer outcomes with metformin-resistant hyperglycemia
Every-Palmer et al (2017)[70]	22-year pharmacovigilance study	n=43,132	160 serious GI hypomotility cases (37/10,000); 18% fatality.	Complications: ileus, perforation, megacolon
Kumar et al (2017)[71]	14-week RCT	n=53 (final n=40)	Clozapine is more effective than quetiapine.	More side effects: sedation, hypersalivation, dizziness, weight gain
Kikuchi et al (2014)[72]	Retrospective observational study	n=26	Seizures (23,1%); EEG abnormalities (38.5%).	Seizures managed without discontinuation.
Gover et al (2020)[73]	Retrospective chart review; hematological monitoring	n=333	Hematologic abnormalities (19.2%), eosinophilia (9.9%), thrombocytopenia (8.2%), anemia (2.1%), and neutropenia (0.6%).	Mostly transient and benign

Abbreviations: ANC, Absolute Neutrophil Count; WBC, White Blood Cell count; CNS, Central Nervous System; NMS, Neuroleptic Malignant Syndrome; CBC, Complete Blood Count; RDW, Red Cell Distribution Width; EHR, Electronic Health Records; BMI, Body Mass Index; GI, Gastrointestinal; HbA1c, Hemoglobin A1c; Hb, Hemoglobin; LFT, Liver Function Test; RFT, Renal Function Test; EEG, Electroencephalogram; RCT, Randomized Controlled Trial; ADR, Adverse Drug Reaction.

Table 3 Quality of Life (QoL) Outcomes in Patients Receiving Clozapine

Author, Year	Country	QoL Tool	Main Findings	Clinical Context / Relevance
Verma et al 2021b [23]	India	WHOQOL-BREF	Significant improvements across all domains: physical, psychological, social, environmental, and overall QoL.	Improvements paralleled by better symptom control and reduced depressive/obsessive features.
Butler et al, 2022[35]	UK	HoNOS, Outpatient visits	Improved mental, physical, and social functioning; reduced healthcare needs.	Reflects enhanced stability and fewer relapses after community-based management.
Verma et al, 2021[36]	India	Patient and caregiver questionnaires	Patients reported improved QoL; caregivers experienced reduced stress and burden.	Indicates psychosocial benefits extending to family well-being due to improved adherence.
Lee et al, 2023[10]	USA	QLS	QoL ↑ 72%; 24% achieved good functioning; ↓ suicidal ideation.	Suggests that functional recovery and reduced suicidality accompany symptom stabilization.
Li et al, 2015[74]	China	QoL questionnaires	No significant QoL difference vs other antipsychotics.	Short follow-up and modest dosing may have limited observable clinical benefit.
Matsuzaki et al, 2023[75]	Japan	Employment data from records	Higher employment rate during clozapine use	Demonstrates social reintegration and functional recovery in TRS patients.
Chan et al, 2023[60]	Hong Kong	Social functioning	Lower cognitive burden with ≤300 mg/day; better daily functioning.	Highlights dose optimization for balanced efficacy and tolerability.

Abbreviations: WHOQOL-BREF, World Health Organization Quality of Life – BREF; HONoS, Health of the Nation Outcome Scales; QLS, Quality of Life Scale; QoL, Quality of Life; TRS, Treatment-Resistant Schizophrenia.

https://doi.org/10.2147/NDT.S566527

Improvements in health-related quality of life (HRQoL) among clozapine-treated patients are partly explained by reduced hospitalization rates, suicide risk, and disease burden.[76] The link between clozapine treatment and improved HRQoL is further supported by its ability to reduce hospitalization rates and overall disease burden. Studies have shown that patients receiving clozapine experience fewer psychiatric hospitalizations and a lower risk of suicide, two critical components in improving quality of life.[77–79]

Comparative analyses show that clozapine yields better psychosocial and QoL outcomes compared to other antipsychotics, as reflected by lower Behavior and Symptom Identification Scale (BASIS) scores and higher Satisfaction with Life Scale (SWLS) scores.[20] Clozapine has also been identified as the atypical antipsychotic offering the greatest improvements in patient quality of life, with the highest utility scores compared to olanzapine, risperidone, ziprasidone, and quetiapine. EQ-5D-3L results indicate fewer problems with mobility, self-care, and daily functioning, reflecting both direct benefits from symptom control and indirect benefits via enhanced stability and adherence.[80]

Caregiver and patient perspectives further highlight systemic benefits: reduced caregiver stress and financial burden, coupled with greater patient satisfaction and engagement.[22,35,75] A longitudinal study by Lee et al (2023) further supports these findings, demonstrating a 72% increase in QoL scores accompanied by a significant reduction in suicidal ideation, highlighting its potential long-term benefits.[10] Another relevant aspect is employment-related functional outcomes. Beyond psychosocial effects, improvements in employment status also reflect functional recovery contributing to QoL. Matsuzaki et al (2023) reported a significant increase in employment rates (regular work and supported employment) during the clozapine phase compared to other antipsychotics. This is critical, as employment serves as a key indicator of social and economic functioning closely tied to overall quality of life.[75]

The available evidence supports the conclusion that clozapine can enhance multiple aspects of QoL in TRS, including psychosocial dimensions, social functioning, and economic independence. However, the variability in findings emphasizes the need for individualized treatment considerations and comprehensive evaluations of social, economic, and cultural contexts. Differences in assessment instruments (eg, WHOQOL-BREF, HONoS, QLS, QoL questionnaires, employment records) also pose challenges for cross-study comparisons. Li et al (2015) found no significant difference in QoL scores between TRS patients receiving clozapine versus non-clozapine antipsychotics, potentially influenced by methodological differences, sample size, or patient characteristics.[74] Similar results were reported in a large national survey in China (2015) analysing over 14,000 patients, which found no significant overall QoL differences despite clozapine being more frequently prescribed to patients with more severe symptoms and earlier onset; side effects such as sedation, hypersalivation, and constipation remained key concerns.[74]

Despite these broad benefits, certain adverse effects may offset quality-of-life gains. Recent research from Barcelona (2023) emphasized that specific side effects of clozapine, such as sialorrhea, can have a meaningful impact on quality of life. With the prevalence of clozapine-induced sialorrhea (CIS) reaching 92%, more than one-third of patients reported moderate to severe QoL reductions due to this symptom, underscoring the need for systematic evaluation and targeted interventions to maintain adherence and treatment outcomes.[51] A study from India found that TRS patients on long-term clozapine therapy had better QoL if they maintained good adherence and cognitive functioning. This suggests that maximizing the benefits of clozapine requires efforts to mitigate negative symptoms, support cognitive function, and enhance adherence.[81] Optimizing clozapine dosing, particularly maintaining ≤300 mg/day or divided doses, appears to support better cognitive and social outcomes, reinforcing the need for individualized management.[60] Overall, evidence indicates that clozapine improves multiple QoL domains through both direct symptomatic relief and indirect functional and social gains; however, side-effect burden and individual variability highlight the importance of personalized approaches.

Economic Outcome of Clozapine

Multiple studies consistently demonstrate clozapine's cost-effectiveness across diverse settings. A mirror cohort study by Butler et al (2022) reported substantial average cost savings of £963 in the first year and £1,598.10 in the second year following community-based initiation of clozapine. Similarly, a cross-sectional study found that approximately 50% of caregivers experienced reductions in caregiving costs after clozapine initiation, suggesting a meaningful alleviation of

caregiver burden and associated indirect costs.[38] These findings suggest that cost benefits extend beyond the health-system level to families.

An observational cohort analysis by Velligan et al (2015) comparing Medicaid beneficiaries with schizophrenia receiving clozapine to those on polypharmacy regimens revealed pronounced economic benefits. Over one year, clozapine use was associated with reductions of $21,233 in total costs, $17,457 in mental health-related costs, and $10,582 in schizophrenia-specific costs. Furthermore, a prospective observational study (Verma, Grover, and Chakrabarti, 2021a) comparing clozapine with other antipsychotics over three months found that while the total cost of illness remained statistically unchanged (INR 40,372 to INR 40,533), direct costs decreased significantly (INR 13,931 to INR 8,757) owing to reductions in hospitalization and polypharmacy. However, provider costs increased markedly (INR 4,512 to INR 15,506) due to enhanced monitoring requirements, indicating a redistribution of costs from patients to the healthcare system. Indirect costs declined non-significantly (INR 21,927 to INR 16,290), but the proportion of family-borne expenses decreased significantly from 88.8% to 61.7%, with 48% of families reporting net reductions in out-of-pocket spending. A summary of key studies evaluating the economic impact of clozapine treatment is presented in Table 4.

Several pharmacoeconomic evaluations further confirm clozapine's cost-effectiveness. A study reported that initiating clozapine therapy can save approximately £3,867 ($5,065) per patient annually, primarily due to reductions in psychiatric hospitalizations and emergency team interventions.[83] Another study showed that clozapine is superior to first-generation antipsychotics such as haloperidol and chlorpromazine, generating savings of up to $38,879 per year while delivering more quality-adjusted life years (QALYs).[84] Although clozapine requires routine blood monitoring due to the risk of agranulocytosis, which can increase healthcare costs, its long-term benefits remain significant. One review noted that despite additional costs for monitoring and healthcare visits, clozapine remains more cost-effective than other antipsychotics. The substantial clinical benefits it offers, particularly for TRS patients, often outweigh these monitoring-related costs.[85] Clozapine monotherapy has also been associated with an average annual cost reduction of $23,025 compared to antipsychotic polypharmacy, making it a more cost-effective option for certain patients with schizophrenia.[86] Real-world analyses such as Butler et al (2022) reaffirm sustained savings through community-based clozapine delivery, primarily via reduced hospitalization and emergency service use.[35]

Delays in initiating clozapine can also lead to increased costs. A study in Japan found that patients who started clozapine ≥20 years after diagnosis had nearly twice the three-year rehospitalization risk (62.2% vs 32.3%) compared to those who began earlier.[45] This underscores the importance of early TRS detection and timely treatment initiation to prevent repeated hospitalization costs. Trials such as the CLEAR Trial in the UK have specifically evaluated the cost-effectiveness of earlier clozapine use in adolescents and young adults.[87] A retrospective cohort study in Japan showed that initiating clozapine therapy ≥20 years after diagnosis increased three-year rehospitalization risk to 62.2%, compared with 32.3% among those who began within ≤9 years. These findings underscore the importance of early TRS

Table 4 Economic Outcomes of Clozapine

Author, Year	Design	Economic Outcome	Clinical Context / Relevance
Butler et al, 2022[35]	Mirror cohort study	Cost savings: £963 (Year 1) and £1,598 (Year 2) after community-based clozapine initiation	Sustained cost reduction through outpatient prescribing and fewer hospitalizations.
Verma et al, 2021[36]	Cross-sectional study	~50% of caregivers reported ↓caregiving costs post-initiation	Reflects indirect savings and ↓ family financial burden.
Velligan et al, 2015[82]	Observational cohort study	Annual cost ↓ $21,233; $17,457 mental health–related, $10,582 schizophrenia-specific	Demonstrates cost-effectiveness vs polypharmacy, and reduced healthcare utilization.
Verma et al, 2021a[22]	Prospective observational	Direct costs ↓ (INR 13,931 → 8,757); provider costs ↑ (INR 4,512 → 15,506)	Indicates redistribution of costs from families to healthcare systems due to monitoring.
Verma et al, 2021a[38]	Prospective observational	Indirect costs ↓ (INR 21,927 → 16,290; ns); family expenses dropped from 88.8% → 61.7%	Suggests improved affordability and reduced financial household burden

Abbreviations: INR, Indian Rupee; TRS, Treatment-Resistant Schizophrenia.

identification and prompt treatment initiation to prevent long-term functional decline. To address this, protocols such as the CLEAR Trial in the UK and the EARLY Trial in Germany have been designed to assess whether earlier initiation can improve patient outcomes, supporting the argument to move clozapine from a last-line to a second-line option.[87]

In the United States, it has also been observed that clinicians often escalate doses or add other antipsychotics before trying clozapine, despite higher costs and lower effectiveness.[88] Improving clinician training and revising treatment guidelines may help optimize clozapine use and reduce total healthcare expenditures. Notably, a study in Canada found that over 68% of patients with a history of non-adherence achieved adherence after starting clozapine, thereby reducing the risk of relapse and emergency service utilization.[89]

While clozapine's side effects may incur indirect costs, they also represent an opportunity for targeted intervention. For example, sialorrhea affected over 90% of patients in a Spanish study, and one-third reported a moderate to severe impact on quality of life.[51] Such issues can reduce work capacity or social functioning, adding to patients' and families' indirect costs. However, other research highlights that the use of clozapine can result in higher laboratory costs for blood-level monitoring. There is also the challenge of limited supporting infrastructure, particularly in public hospitals. Many general hospitals lack the necessary facilities and systems to safely administer clozapine, including the capacity for routine blood testing and monitoring for side effects.[54] Similar findings have been reported elsewhere, where average clozapine use remains low (~18.4%) due to mandatory blood monitoring and limited infrastructure.[55]

Barriers to Clozapine Use

Clozapine is widely recognized as the gold-standard treatment for TRS, yet its use remains suboptimal in many parts of the world. Despite its effectiveness, clozapine carries a risk of agranulocytosis, necessitating regular blood monitoring. This risk has led to its designation as a third-line treatment.[47] Recent evidence indicates that the hematologic risks associated with clozapine are highest during the first six months of treatment and decline substantially thereafter.[31] Reflecting this pattern, several international guidelines now support less intensive absolute neutrophil count (ANC) monitoring for stable patients after the first year.[90] For example, UK practice has adopted monthly monitoring after one year of stability, and recent FDA updates to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) have emphasized individualized, risk-based monitoring rather than centralized reporting.[91,92] These changes highlight a shift toward balancing safety with accessibility and may help address monitoring-related barriers, particularly in resource-limited settings. Clozapine is also associated with other serious adverse effects such as myocarditis, seizures, sedation, and metabolic changes.[48–50] Another significant barrier is sialorrhea. A study in Spain found its prevalence to be as high as 92.3%, with one-third of patients reporting moderate to severe impacts on quality of life. This side effect demands systematic evaluation and proactive management to avoid undermining treatment adherence.[51]

Clozapine's cardiovascular impact is another concern. A US study showed increases in diastolic blood pressure and heart rate, with hypertension rising from 22% to 67% and tachycardia from 33% to 83%, necessitating careful cardiovascular monitoring.[52] In Yogyakarta, Indonesia, Raharjeng et al (2023) reported significant side effects of clozapine, including dizziness, vomiting, diarrhea, hypersalivation, weight gain, and sedation. Nevertheless, this study found clozapine to be relatively safe overall, with adverse events occurring in 16.07% of 336 patients. Most side effects were manageable without discontinuation: 72.2% of patients required adjunctive treatment, 24.1% required no additional therapy, and only 3.7% needed to stop treatment.[53]

Barriers also arise at both prescriber and health system levels. A survey of 100 psychiatrists in Karachi, Pakistan, found that 70% felt uncomfortable prescribing clozapine due to concerns about serious side effects, complex laboratory monitoring, and lack of specific training. Notably, 100% of those who had received training felt comfortable prescribing it, compared with just 6.4% among those without training, highlighting the critical role of educational interventions to improve prescriber competence.[54] In many low- and middle-income countries, usage remains limited. The REAP Survey reported an average clozapine use rate of only 18.4%, with significant variation between countries (2.6% in Japan vs 32.3% in Hong Kong). Key barriers included limited blood-monitoring infrastructure, low service reimbursement that reduced institutional incentives, and a lack of local guideline adaptation to real-world practice settings.[55]

Certain populations require special consideration. In older adults (>65 years), clozapine use requires slower titration and lower doses (25–100 mg/day) to minimize the risks of orthostatic hypotension, sedation (which increases the risk of

falls), anticholinergic effects such as constipation and delirium, and aspiration pneumonia due to hypersalivation.[56,57] Gender differences also influence side-effect profiles. An Italian study found women more frequently experienced constipation, orthostatic hypotension, and abdominal obesity, while men were more prone to tachycardia and hypertriglyceridemia. This highlights the importance of gender-sensitive monitoring and side-effect management to improve tolerability and adherence.[58]

Behavioral factors and drug interactions further complicate clozapine use. A study in Japan found that smoking increased relapse risk among clozapine-treated patients (aHR = 2.27), which was dramatically higher when combined with valproic acid (aHR = 5.32). This underscores the need for a comprehensive assessment of patients' daily behaviors, such as smoking and cautious selection of combination therapies, especially with valproate in patients on clozapine.[59] Moreover, the TRRIP Consensus emphasizes ensuring plasma clozapine levels of ≥350 ng/mL before initiating augmentation. Agents such as amisulpride or aripiprazole are recommended for positive symptoms, SSRIs for negative symptoms, alongside psychosocial interventions such as CBT. However, real-world implementation is often hindered by individual response variability and the intensive monitoring required.[8] Research in Hong Kong supports using ≤300 mg/day dosing and multiple daily dosing to minimize cognitive side effects and enhance social functioning, reinforcing the need for personalized treatment strategies.[60] Overall, clozapine remains the first-line choice with unmatched efficacy for TRS. However, its use requires addressing multidimensional barriers, including prescriber training, subsidized laboratory monitoring costs, the development of dedicated clinics, local guideline adaptation, and age-, gender-, and comorbidity-sensitive side-effect management. A systematic and integrated approach is needed to ensure wider, safer, and more equitable access to clozapine therapy.

Psychiatric pharmacists have a strategic role in overcoming barriers to clozapine use by enhancing prescriber knowledge, managing and minimizing side effects through vigilant monitoring, ensuring patient adherence through education and ongoing support, and advocating for inclusion of clozapine in formularies to broaden access. Additionally, implementing interprofessional care models can improve coordination among healthcare providers, significantly enhancing patient outcomes. Psychiatrists also play a crucial role by strengthening clinical training on the use of clozapine, optimizing safety and side-effect management, and fostering shared decision-making with patients to improve acceptance and treatment outcomes. At the system level, support is needed through increased resources and provider training, development of structured and efficient care pathways, and awareness campaigns promoting clozapine as an effective treatment option, including for younger patients with severe mental illness. Identifying existing barriers, clinical, administrative, and systemic, and implementing supportive structural changes are critical steps toward optimizing clozapine utilization in clinical practice.[14,61,62]

Despite the robust evidence supporting clozapine's efficacy, several areas of uncertainty remain. Long-term safety data, particularly regarding metabolic complications, cardiovascular effects, and mortality trends, remain limited and heterogeneous across studies.[93–95] Furthermore, implementation in resource-limited settings is challenged by infrastructure gaps, inconsistent monitoring capacity, and variable policy support.[96,97] Addressing these issues through pragmatic, region-specific studies and implementation research will be essential to translate clozapine's proven efficacy into equitable real-world outcomes.[98]

Practical Recommendations for Clinical Practice and Policy

Given the robust evidence base demonstrating clozapine's unique clinical, economic, and quality-of-life benefits, it is essential to translate these findings into actionable strategies for practice and policy. Psychiatrists should prioritize early identification of treatment-resistant schizophrenia and consider clozapine initiation without unnecessary delays, while ensuring careful monitoring of hematological and cardiometabolic risks.[99] Integrating shared decision-making with patients and families can improve acceptance and adherence.[100,101] Pharmacists play a pivotal role in supporting safe clozapine use by conducting medication reviews, monitoring for adverse effects and drug interactions, and providing structured education to patients and caregivers on adherence, side-effect management, and lifestyle modification.[102] Their involvement in multidisciplinary teams can help reduce hospital readmissions and optimize long-term outcomes. At the system level, policymakers should strengthen infrastructure for routine blood monitoring, subsidize laboratory and follow-up costs, and invest in training programs to increase prescriber confidence.[103] Developing context-sensitive

national guidelines, particularly in low- and middle-income countries, is critical to harmonize practice, reduce inequities in access, and ensure sustainable financing of clozapine programs.[104,105] By aligning clinical practice with system-level support, these strategies can maximize the clinical, economic, and quality-of-life benefits of clozapine globally.

Conclusion

Clozapine remains the most effective and evidence-based treatment for treatment-resistant schizophrenia, offering clear advantages over other antipsychotics in controlling symptoms, reducing suicidality, and improving social and occupational functioning. This review underscores its multidimensional benefits, encompassing clinical, quality-of-life, and economic gains that together demonstrate its cost-effectiveness and broad therapeutic value. Despite these well-established advantages, clozapine remains underused because of safety concerns, mandatory monitoring, limited prescriber training, infrastructural barriers, and persistent stigma. Overcoming these obstacles requires coordinated strategies that include clinician education, dedicated monitoring systems, interprofessional collaboration, and context-sensitive guidelines addressing patient diversity and resource variation. Early identification of TRS and timely clozapine initiation can further prevent chronicity, reduce relapses, and enhance long-term recovery. Future research should prioritize longitudinal, real-world evaluations that integrate clinical, patient-reported, and economic outcomes while assessing the effectiveness of strategies to overcome implementation barriers. Additionally, systematic reviews focusing on quality-of-life and economic outcomes are needed to strengthen the current evidence base and inform future clinical and policy decisions. Future studies should also examine implementation models across different healthcare contexts to identify scalable strategies that balance safety monitoring with accessibility.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. *J Clin Psychiatry*. 2021;82.
2. Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. *Pharmgenomics Pers Med*. 2016;9:117. doi:10.2147/PGPM.S115741
3. Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. *Can J Psychiatry*. 2017;62 (9):604–616. doi:10.1177/0706743717720448
4. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry*. 2017;174(3):216–229. doi:10.1176/appi.ajp.2016.16050503
5. Diniz E, Fonseca L, Rocha D, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. *Brazilian J Psychiatry*. 2023;45:448. doi:10.47626/1516-4446-2023-3126
6. Detanac M, Williams C, Dragovic M, Shymko G, John AP. Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates. *Aust N Z J Psychiatry*. 2024;58(12):1080–1089. doi:10.1177/00048674241274314
7. Duru EE, Ben-Umeh KC, Mattingly TJ. Cost of long-term care and balancing caregiver wellbeing: a narrative review. *Expert Rev Pharmacoecon Outcomes Res*. 2024;24:883–897. doi:10.1080/14737167.2024.2383406
8. Wagner E, Kane JM, Correll CU, et al. Clozapine combination and augmentation strategies in patients with schizophrenia —recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group. *Schizophr Bull*. 2020;46 (6):1459–1470. doi:10.1093/schbul/sbaa060
9. Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. *Br Med Bull*. 2020;135:73–89. doi:10.1093/bmb/ldaa024
10. Lee MA, Cola P, Jayathilake K, Meltzer HY. Long-term outcome of clozapine in treatment-resistant schizophrenia. *J Clin Psychopharmacol*. 2023;43:211–219. doi:10.1097/JCP.0000000000001671
11. Stanton RJ, Paxos C, Geldenhuys WJ, et al. Clozapine underutilization in treatment-resistant schizophrenia. *Mental Health Clinician*. 2015;5 (2):63–67. doi:10.9740/mhc.2015.03.063
12. Freibüchler A, Seifert R. Analysis of clinical studies on clozapine from 2012-2022. *Naunyn Schmiedebergs Arch Pharmacol*. 2024;397 (12):9745–9765. doi:10.1007/s00210-024-03209-1
13. Kütük O. Use of clozapine in the treatment-resistant schizoprenia. *J Experi Basic Med Sci*. 2020;1(1):36–41. doi:10.5606/jebms.2020.75609
14. Bittner RA, Reif A, Qubad M. The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry. *Curr Opin Psychiatry*. 2023;36:327–336. doi:10.1097/YCO.0000000000000871
15. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. *Ann Hematol*. 2020;99:2477. doi:10.1007/s00277-020-04215-y
16. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *British Journal of Psychiatry*. 2016;209:385–392. doi:10.1192/bjp.bp.115.177261

17. van der Horst MZ, de Boer N, Müderrisoğlu A, et al. Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN). *Schizophrenia*. 2025;11(1):1–8. doi:10.1038/s41537-025-00570-9
18. Fenton C, Kang C. Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management. *Drugs Therap Perspective*. 2023;39(3):107. doi:10.1007/s40267-023-00982-6
19. Verdoux H, Lepetit A, de Leon J. Clozapine for older adults with severe mental illness: a systematic review and expert recommendations for clinical practice. *Expert Rev Clin Pharmacol*. 2025;18:385–396. doi:10.1080/17512433.2025.2520926
20. Choe E, Choe E, Choe AY, Kim E. Associations of clozapine use with psychosocial functioning and quality of life in patients with schizophrenia: a community-based cross-sectional study. *Psychiatry Investig*. 2021;18:968–976. doi:10.30773/pi.2021.0190
21. Gören JL, Rose AJ, Smith EG, Ney JP. The business case for expanded clozapine utilization. *Psychiatric Services*. 2016;67:1197–1205. doi:10.1176/appi.ps.201500507
22. Verma M, Grover S, Chakrabarti S. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. *Nord J Psychiatry*. 2021;75:135–144. doi:10.1080/08039488.2020.1811374
23. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. *Can J Psychiatry*. 2017;62:772–777. doi:10.1177/0706743717718167
24. Kitagawa K, Uekusa S, Hanai Y, et al. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: a 12-year prescription survey pre- and post-introduction of clozapine. *Asian J Psychiatr*. 2024;96:104047. doi:10.1016/j.ajp.2024.104047
25. Jethwa KD. Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm. *BJPsych Adv*. 2015;21:342–344. doi:10.1192/apt.bp.114.013797
26. Fontanella CA, Campo JV, Phillips GS, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. *J Clin Psych*. 2016;77:661–667. doi:10.4088/JCP.15m10271
27. McQueen G, Sendt K-V, Gillespie A, et al. Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia. *Schizophr Bull*. 2021;47(3):662–671. doi:10.1093/schbul/sbaa156
28. Chui MKK, Schneider K, Miclau K, et al. Associations of systemic inflammation and senescent cell biomarkers with clinical outcomes in older adults with schizophrenia. *medRxiv*. 2024. doi:10.1101/2024.03.06.24303857
29. Northwood K, Pearson E, Arnautovska U, et al. Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis. *Br J Psychiatry*. 2023;222(6):241–245. doi:10.1192/bjp.2023.27
30. Griffiths K, Mellado MR, Chung R, et al. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. *Brain Behav Immun*. 2024;115:223–228. doi:10.1016/j.bbi.2023.10.001
31. Qubad M, Bittner RA. Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. *Ther Adv Psychopharmacol*. 2023;13. doi:10.1177/20451253231158152
32. Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. *Int Clin Psychopharmacol*. 2017;32:169–173. doi:10.1097/YIC.0000000000000160
33. Marder SR. Community evidence of clozapine's effectiveness. *Am J Psychiatry*. 2016;173:103–104. doi:10.1176/appi.ajp.2015.15111466
34. Morrison PD, Jauhar S, Young AH. The mechanism of action of clozapine. *J Psychopharmacol*. 2025;39(4):297–300. doi:10.1177/02698811251319458
35. Butler E, Pillinger T, Brown K, et al. Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. *Br J Psychiatry*. 2022;221:740–747. doi:10.1192/bjp.2022.47
36. Verma M, Grover S, Dua D, Dua D. Attitude towards and experience with clozapine of patients and their caregivers after three months of starting of clozapine. *Nord J Psychiatry*. 2021;75:336–343. doi:10.1080/08039488.2020.1857832
37. Kim JH, Lee J, Kim YB, Han AY. Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine. *Compr Psychiatry*. 2014;55:708–713. doi:10.1016/j.comppsych.2013.11.002
38. Verma M, Grover S, Chakrabarti S. Cost of the illness of treatment-resistant schizophrenia. *J Clin Psychopharmacol*. 2021;41:36–44. doi:10.1097/JCP.0000000000001332
39. Pridan S, Swartz M, Baruch Y, et al. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. *Int Psychogeriatr*. 2015;27(1):131–134. doi:10.1017/S1041610214001756
40. Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry*. 2019;76(5):499. doi:10.1001/jamapsychiatry.2018.4320
41. Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. *Am J Psych*. 2017;174(10):990–998. doi:10.1176/appi.ajp.2017.16091097
42. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. *JAMA Psychiatry*. 2017;74(7):686. doi:10.1001/jamapsychiatry.2017.1322
43. Vieira JCM, Reis EA, Guerra AA, Oliveira HND, Ruas CM. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia. *Front Psychiatry*. 2024;15. doi:10.3389/fpsyt.2024.1421501
44. Cho J, Hayes RD, Jewell A, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. *Acta Psychiatr Scand*. 2019;139:237–247. doi:10.1111/acps.12989
45. Hatano M, Kamei H, Takeuchi I, et al. Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study. *BMC Psychiatry*. 2023;23(1). doi:10.1186/s12888-023-05176-y.
46. Peitl V, Filippova KO, Ermakov AM, et al. Clozapine in treatment-resistant schizophrenia and its augmentation with electroconvulsive therapy in ultra-treatment-resistant schizophrenia. *Biomedicines*. 2023;12:11. doi:10.3390/biomedicines12010011
47. Park SI, Lim HS, Kim E, Lim H-S, Kim E. Modeling approach with therapeutic drug monitoring data to describe time course of clozapine exposure and positive and negative syndrome scale scores. *Ther Drug Monit*. 2023;45:417–424. doi:10.1097/FTD.0000000000001030
48. Dionisie V. Clozapine—serious adverse effects and clinical management. *Antidotes Toxins Drugs*. 2024;329–355. doi:10.1016/B978-0-12-824472-2.00012-9
49. Jaballah F, Aissa A, Ouali U, Zgueb Y, Jomli R. Clozapine-induced stuttering: case report and literature review. *Pharmacopsychiatry*. 2023;56:240–243. doi:10.1055/a-2189-5597

50. Tsenteradze T, Kochiashvili G, Gabadadze M, Kalmakhelidze D, Zaalishvili Z. Selected neurologic and psychiatric outcomes in patients treated with clozapin (Review article). *Experi Clinl Med Georgia*. 2022. doi:10.52340/JECM.2022.02.21
51. Sanagustin D, Martin-Subero M, Hogg B, et al. Prevalence of clozapine-induced sialorrhea and its effect on quality of life. *Psychopharmacology*. 2023;240(1):203–211. doi:10.1007/s00213-022-06294-3
52. Norman SM, Sullivan KM, Liu F, et al. Blood pressure and heart rate changes during clozapine treatment. *Psychiatr Q*. 2017;88(3):545. doi:10.1007/s11126-016-9468-5
53. Rahajeng B, Sari BC, Maziyyah N. Patient safety: adverse effects of clozapine and their management at the psychiatric hospital Ghrasia in Yogyakarta, Indonesia. *J Med Life*. 2023;16:1652–1657. doi:10.25122/jml-2023-0145
54. Shad MU, Hasan S. Barriers to clozapine use in treatment-refractory populationin Karachi, Pakistan. *J Pak Psychiatr Soc*. 2023;20:4–9. doi:10.63050/jpps.20.04.283
55. Xu SW, Dong M, Zhang Q, et al. Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016). *Psychiatry Res*. 2020;287:112271. doi:10.1016/j.psychres.2019.02.056
56. Kirrane A, Majumdar B, Richman A. Clozapine use in old age psychiatry. *BJPsych Adv*. 2018;24:204–211. doi:10.1192/bja.2017.26
57. Wellesley Wesley E, Patel I, Kadra-Scalzo G, et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. *Schizophr Res*. 2021;232:68–76. doi:10.1016/j.schres.2021.05.006
58. Martini F, Spangaro M, Buonocore M, et al. Clozapine tolerability in treatment resistant schizophrenia: exploring the role of sex. *Psychiatry Res*. 2021;297:113698. doi:10.1016/j.psychres.2020.113698
59. Tsukahara M, So R, Yoshimura Y, et al. Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: a 1-year retrospective cohort study. *Acta Psychiatr Scand*. 2023;148(5):437–446. doi:10.1111/acps.13612
60. Chan SKW, Suen YN, Yan WC, et al. Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. *European Neuropsychopharmacology*. 2023;75:67–79. doi:10.1016/j.euroneuro.2023.07.007
61. Walker G, Lang J, Smith H. Survey on barriers to psychiatrists' use of clozapine for young people in Scotland and suggestions for reducing these. *PLoS One*. 2024;19:e0304996. doi:10.1371/journal.pone.0304996
62. Kelly DL, Love RC. Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management. *Mental Health Clinician*. 2019;9:64–69. doi:10.9740/mhc.2019.03.064
63. Kelly DL, Glassman M, Wonodi I, et al. Clozapine and neutrophil response in patients of African descent: a six-month, multinational, prospective, open-label clinical trial. *Schizophr Res*. 2024;268:312–322. doi:10.1016/j.schres.2023.08.002
64. Chandru P, Gunja N. Toxicity and adverse effects in clozapine-related presentations to a medical toxicology service in Western Sydney. *J Med Toxicol*. 2023;19:374–380. doi:10.1007/s13181-023-00963-1
65. Iqbal E, Govind R, Romero A, et al. The side effect profile of Clozapine in real world data of three large mental health hospitals. *PLoS One*. 2020;15(12):e0243437. doi:10.1371/journal.pone.0243437
66. Harjaningsih W, Ikawati Z, Khoirunnisa RS, et al. Correlation between clozapine use and metabolic syndrome in schizophrenic patients. *Pharmacy Education*. 2023;23(2):103–112. doi:10.46542/pe.2023.232.103112
67. Imazu S, Hata T, Toyoda K, et al. Safety profile of clozapine: analysis using national registry data in Japan. *J Psychiatr Res*. 2021;141:116–123. doi:10.1016/j.jpsychires.2021.06.041
68. de Filippis R, Gaetano R, Schoretsanitis G, et al. Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile. *Neuropsychiatr Dis Treat*. 2021;17:2141–2150. doi:10.2147/NDT.S312095
69. Zhuo C, Xu Y, Wang H, et al. Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. *J Affect Disord*. 2021;295:163–172. doi:10.1016/j.jad.2021.08.023
70. Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal 'slow gut' reactions, and comparison with international drug safety advice. *CNS Drugs*. 2017;31:699. doi:10.1007/s40263-017-0448-6
71. Kumar M, Chavan B, Sidana A, Das S. Efficacy and tolerability of clozapine versus quetiapine in treatment-resistant schizophrenia. *Indian J Psychol Med*. 2017;39(6):770–776. doi:10.4103/IJPSYM.IJPSYM_111_17
72. Kikuchi YS, Sato W, Ataka K, et al. Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia. *Neuropsychiatr Dis Treat*. 2014;10:1973–1978. doi:10.2147/NDT.S69784
73. Grover S, Shouan A, Chakrabarti S, Avasthi A. Haematological side effects associated with clozapine: a retrospective study from India. *Asian J Psychiatr*. 2020;48:101906. doi:10.1016/j.ajp.2019.101906
74. Li Q, Xiang Y-T, Su Y-A, et al. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: findings of the three national surveys on use of psychotropic medications in China (2002-2012). *Schizophr Res*. 2015;168:523–529. doi:10.1016/j.schres.2015.07.048
75. Matsuzaki H, Hatano M, Iwata M, Saito T, Yamada S. Effectiveness of clozapine on employment outcomes in treatment-resistant schizophrenia: a retrospective bidirectional mirror-image study. *Neuropsychiatr Dis Treat*. 2023;19:615–622. doi:10.2147/NDT.S402945
76. Percinel I, Yazici KU, Erermis HS, et al. The role and efficacy of clozapine treatment in early-onset and very early-onset schizophrenia cases: discussion of five cases. *Klinik Psikofarmakoloji Bülteni-Bulletin Clin Psychopharmacol*. 2015;25(1):65–73. doi:10.5455/bcp.20141008011231
77. Land R, Siskind D, McArdle P, et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2017;135(4):296–309. doi:10.1111/acps.12700
78. De Berardis D, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. *Ther Adv Drug Saf*. 2018;9(5):237. doi:10.1177/2042098618756261
79. Sampogna G, Di Vincenzo M, Giuliani L, et al. A systematic review on the effectiveness of antipsychotic drugs on the quality of life of patients with schizophrenia. *Brain Sci*. 2023;13(11):1577. doi:10.3390/brainsci13111577
80. de Almeida JL, Zuppo IDF, Castel S, et al. Health-related quality of life in patients treated with atypical antipsychotics. *Brazilian J Psych*. 2020;42(6):599. doi:10.1590/1516-4446-2019-0739
81. Nandakumar D, Ganesh R, Deb KS, Jain R, Sood M. Disability and quality of life in patients with treatment-resistant schizophrenia on long-term clozapine therapy. *Indian J Psychiatry*. 2023;65(6):694–697. doi:10.4103/indianjpsychiatry.indianjpsychiatry_320_22

82. Velligan DI, Carroll C, Lage MJ, Fairman K. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. *Psychiatr Serv*. 2015;66:127–133. doi:10.1176/appi.ps.201300085
83. de Silva PN. Variations in secondary health resource utilisation post Clozapine initiation. 2020. doi:10.1101/2020.05.16.20103929
84. Zhou J, Millier A, François C, Aballéa S, Toumi M. Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. *J Mark Access Health Policy*. 2019;7:1648973. doi:10.1080/20016689.2019.1648973
85. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. *BMC Psychiatry*. 2014;14(1):1–5. doi:10.1186/1471-244X-14-102
86. Martin A, Bessonova L, Hughes R, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. *Adv Ther*. 2022;39(9):3933–3956. doi:10.1007/s12325-022-02232-z
87. Casetta C, Santosh P, Bayley R, et al. CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. *BMC Psychiatry*. 2024;24(1). doi:10.1186/s12888-023-05397-1.
88. Nasrallah HA, Fedora R, Morton R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. *Schizophr Res*. 2019;208:217–220. doi:10.1016/j.schres.2019.02.018
89. Brodeur S, Courteau J, Vanasse A, et al. Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. *British Journal of Psychiatry*. 2022;220(6):347–354. doi:10.1192/bjp.2022.1
90. Siskind D, Northwood K, Pillinger T, et al. Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel. *Lancet Psychiatry*. 2025. doi:10.1016/S2215-0366(25)00098-7
91. Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. *Clin Psychopharmacol Neurosci*. 2016;14(4):323. doi:10.9758/cpn.2016.14.4.323
92. FDA. Information on clozapine. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-clozapine. Accessed November 05, 2025.
93. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. *Schizophr Bull*. 2019;45(2):315–329. doi:10.1093/schbul/sby052
94. Wagner E, Siafis S, Fernando P, et al. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. *Transl Psychiatry*. 2021;11(1):1–18. doi:10.1038/s41398-021-01613-2
95. Taub S, Hoshen M, Balicer R, et al. Metabolic predictors for mortality among patients treated with long-term clozapine – a longitudinal study. *Eur Neuropsychopharmacol*. 2020;41:63–69. doi:10.1016/j.euroneuro.2020.09.002
96. Ogbuagu O, et al. Expanding access to mental health in low-resource settings: strategies for policy, supply chain, and implementation. Available from: https://www.researchgate.net/publication/390209110. Accessed November 05, 2025.
97. Alfaqeeh M, Alfian SD, Abdulah R. Sociodemographic factors, health-risk behaviors, and chronic conditions are associated with a high prevalence of depressive symptoms: findings from the indonesian family life survey-5. *Behavioral Medicine*. 2024;51:117–127. doi:10.1080/08964289.2024.2375205
98. McIntyre RS, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. 2021;178:383–399.
99. Samara M, Alevizopoulos G, Bozikas VP, et al. Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities. *Expert Rev Neurother*. 2025;25(5):505–519. doi:10.1080/14737175.2025.2484434
100. Fiorillo A, Barlati S, Bellomo A, et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. *Ann Gen Psychiatry*. 2020;19(1):1–12. doi:10.1186/s12991-020-00293-4
101. Alfaqeeh M, Abdullah R, Zakiyah N, et al. Medication adherence and contributing factors in patients with heart failure within the middle east: a systematic review. *Glob Heart*. 2025;20:47. doi:10.5334/gh.1431
102. Alfaqeeh M, Santoso P, Alffenaar JW, Pradipta IS. A call to action: empowering pharmacists in drug-resistant tuberculosis management. *J Multidiscip Healthc*. 2025;18:3531–3544. doi:10.2147/JMDH.S517965
103. Hamm BM, Conley VM. Improving access to laboratory monitoring in individuals living with serious mental illness. *Issues Ment Health Nurs*. 2019;40:917–921. doi:10.1080/01612840.2019.1652870
104. Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. *Psychiatric Services*. 2018;69:224–227. doi:10.1176/appi.ps.201700162
105. Khairinisa MA, Alfaqeeh M, Rafif SN, Muljono FO, Colin MN. Cannabis and other substance misuse: implications and regulations. *Toxics*. 2023;11(9):756. doi:10.3390/toxics11090756